Basic fibroblast growth factor and hypertensive disorders in pregnancy

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biochemistry

Background:

• Hypertensive disorders in pregnancy, including preeclampsia, represent a significant maternal health concern.
• Accurate differentiation between mild and severe preeclampsia is crucial for appropriate clinical management.
• Basic fibroblast growth factor (bFGF) is a protein with potential roles in vascular function and pregnancy complications.

Purpose of the Study:

• To investigate serum concentrations of basic fibroblast growth factor (bFGF) in pregnant women with various hypertensive disorders.
• To determine if serum bFGF levels can serve as a diagnostic marker to differentiate between mild and severe preeclampsia.

Main Methods:

• A prospective cohort study involving 120 pregnant women.
• Serum bFGF concentrations were measured in four groups: healthy pregnant women, women with chronic hypertension, women with mild preeclampsia, and women with severe preeclampsia.
• Statistical analysis, including logistic regression, was employed to assess the association between bFGF levels and preeclampsia severity.

Main Results:

• Median serum bFGF concentrations varied across groups, with a notable difference observed between healthy pregnant women and those with mild preeclampsia (P=0.02).
• Logistic regression analysis indicated that serum bFGF concentration significantly influenced the diagnosis of mild preeclampsia (P=0.01).
• Serum bFGF levels did not show a significant association with the diagnosis of chronic hypertension (P=0.19) or severe preeclampsia (P=0.41).

Conclusions:

• Elevated serum bFGF concentrations are associated with mild preeclampsia.
• Serum bFGF is not a discriminatory biomarker for distinguishing between mild and severe preeclampsia.
• Further research may explore the role of bFGF in the pathophysiology of mild preeclampsia.